Literature DB >> 3506819

A simple quantitative HPLC assay for ifosfamide in biological fluids.

J M Margison1, P M Wilkinson, T Cerny, N Thatcher.   

Abstract

A high performance liquid chromatography method is described for measuring Ifosfamide (I) in human serum. This involves solvent extraction, reverse phase HPLC and UV detection at 190 nm. Standard curves of peak height x detector sensitivity versus I concentration in serum were linear with a lower limit of detection of 100 ng/ml. Authentic 14C-labelled I cochromatographed with standard I and with I found in serum from treated patients. The concentration-time curves of I determined by both HPLC and gas chromatography were indistinguishable. We conclude that this method is suitable for determining I pharmacokinetics in biological specimens.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3506819     DOI： 10.1002/bmc.1130010303

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN： 0269-3879            Impact factor:   1.902


  11 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

Authors:  J A Radford; J M Margison; R Swindell; M J Lind; P M Wilkinson; N Thatcher
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  The effect of age on the pharmacokinetics of ifosfamide.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

4.  The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

Authors:  J A Radford; J M Margison; R Swindell; M J Lind; P M Wilkinson; N Thatcher
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

7.  Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.

Authors:  T Cerny; A Graf; P Rohner; T Zeugin; K W Brunner; A Küpfer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.

Authors:  T M Loeffler; F W Weber; T U Hausamen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Bioavailability of ifosfamide in patients with bronchial carcinoma.

Authors:  T Cerny; J M Margison; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 10.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.